ProQR Therapeutics NV (PRQR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1137926,
    "name": "ProQR Therapeutics NV",
    "stock_name": "ProQR Therapeutics NV",
    "full_name": "ProQR Therapeutics NV",
    "name_url": "stocks-analysis/proqr-therapeutics-nv",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "2.12",
    "chg": 0.17,
    "chgp": "8.72%",
    "dir": 1,
    "prev_price": "1.95",
    "mcapval": "253.79",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "NL0010872495",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.54 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/proqr-therapeutics-nv-1137926-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is ProQR Therapeutics NV technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-proqr-therapeutics-nv-technically-bullish-or-bearish-3547476",
        "imagepath": "",
        "date": "2025-09-20 19:56:07",
        "description": "As of 11 September 2025, the technical trend for ProQR Therapeutics NV has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The Bollinger Bands also reflect a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but is mildly bearish monthly, and Dow Theory indicates a mildly bearish stance on both time frames. The daily moving averages are mildly bullish, suggesting short-term support.\n\nIn terms of performance, ProQR has a year-to-date return of -17.36%, underperforming the S&P 500's 12.22%, but it has outperformed the index over the past year with a return of 21.67% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but with mixed signals from various indicators...."
      },
      {
        "title": "Is ProQR Therapeutics NV overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-proqr-therapeutics-nv-overvalued-or-undervalued-3543829",
        "imagepath": "",
        "date": "2025-09-20 18:29:52",
        "description": "As of 4 November 2021, the valuation grade for ProQR Therapeutics NV moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.44, an EV to EBIT of -1.92, and an EV to Sales ratio of 3.42, which indicate significant challenges in profitability and valuation relative to its sales.\n\nIn comparison to its peers, ProQR Therapeutics NV has a P/E ratio of -5.81, while Esperion Therapeutics, Inc. has a P/E of -4.99, and Ocugen, Inc. stands at -5.65, all reflecting a risky valuation environment in the biotechnology sector. Despite a strong 3-year return of 192.0%, which outperformed the S&P 500's 70.41% return, the year-to-date performance of -17.36% suggests ongoing struggles that reinforce the notion of overvaluation...."
      }
    ],
    "total": 7,
    "sid": "1137926",
    "stock_news_url": "https://www.marketsmojo.com/news/proqr-therapeutics-nv-1137926"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is ProQR Therapeutics NV technically bullish or bearish?

2025-09-20 19:56:07

As of 11 September 2025, the technical trend for ProQR Therapeutics NV has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating some positive momentum. The Bollinger Bands also reflect a mildly bullish stance on both weekly and monthly time frames. However, the KST shows a bullish weekly signal but is mildly bearish monthly, and Dow Theory indicates a mildly bearish stance on both time frames. The daily moving averages are mildly bullish, suggesting short-term support. In terms of performance, ProQR has a year-to-date return of -17.36%, underperforming the S&P 500's 12.22%, but it has outperformed the index over the past year with a return of 21.67% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but with mixed signals from various indicators....

Is ProQR Therapeutics NV overvalued or undervalued?

2025-09-20 18:29:52

As of 4 November 2021, the valuation grade for ProQR Therapeutics NV moved from does not qualify to risky. The company is currently overvalued based on its financial metrics. Key ratios include a Price to Book Value of 2.44, an EV to EBIT of -1.92, and an EV to Sales ratio of 3.42, which indicate significant challenges in profitability and valuation relative to its sales. In comparison to its peers, ProQR Therapeutics NV has a P/E ratio of -5.81, while Esperion Therapeutics, Inc. has a P/E of -4.99, and Ocugen, Inc. stands at -5.65, all reflecting a risky valuation environment in the biotechnology sector. Despite a strong 3-year return of 192.0%, which outperformed the S&P 500's 70.41% return, the year-to-date performance of -17.36% suggests ongoing struggles that reinforce the notion of overvaluation....

View All News